Clinical trial
Telavancin for Treatment of Uncomplicated Staphylococcus Aureus Bacteremia
NCT00062647 · Cumberland Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00062647 |
|---|---|
| Title | Telavancin for Treatment of Uncomplicated Staphylococcus Aureus Bacteremia |
| Official title | A Phase 2, Randomized, Double-Blind, Parallel-Group, Multinational Trial of Intravenous Televancin (TD-6424) for Treatment of Uncomplicated Staphylococcus Aureus Bacteremia |
| Acronym | ASSURE |
| Lead sponsor | Cumberland Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Gram-Positive Bacterial Infections |
| Intervention type | Drug |
| Interventions | Telavancin, Vancomycin, nafcillin, oxacillin, or cloxacillin |
| Enrollment | 60 |
| Start date | Aug 1, 2003 |
| Primary completion | Aug 1, 2006 |
| Completion | Aug 1, 2006 |
| First posted | Jun 12, 2003 |
| Last update posted | Jan 16, 2019 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: